| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | Icotrokinra (JNJ-2113) - (ANTHEM-UC) | Ulcerative colitis | Phase 2b | Data Released | Oral | Gastroenterology |
| Johnson & Johnson | Seltorexant - (MIN-202) | Primary insomnia | Phase 2b | Trial Completed | Oral | Psychiatric |
| Johnson & Johnson | HVTN 705/HPX2008 (Imbokodo) | HIV in Women | Phase 2b | Intramuscular | Anti-HIV | |
| Johnson & Johnson | PN-235 (JNJ-77242113) - (FRONTIER 1) | Plaque psoriasis | Phase 2b | Data Released | Oral | Immunology: Anti-TNF |
| Johnson & Johnson | TALVEY (talquetamab-tgvs) and TECVAYLI (teclistamab-cqyv) - (RedirecTT-1 ) | Multiple Myeloma | Phase 2 | Data Released | Subcutaneous | Oncology |
| Johnson & Johnson | JNJ-4804 - (AFFINITY) | Psoriatic Arthritis | Phase 2 | Ongoing | oral | Immunology: Anti-TNF |
| Johnson & Johnson | Nipocalimab - (DAHLIAS) | Sjögren's disease (SjD) | Phase 2 | Data Released | Intravenous | Immunology |
| Johnson & Johnson | NM26 | Atopic dermatitis (AD) | Phase 2 | Trial Planned | Intravenous | Immunology |